Department of Kinesiology, Pennsylvania State University, University Park, PA, USA.
Hypertension. 2011 Nov;58(5):935-42. doi: 10.1161/HYPERTENSIONAHA.111.178129. Epub 2011 Sep 19.
Essential hypertension is a proinflammatory, proconstrictor disease coinciding with endothelial dysfunction and inward vessel remodeling. Using the skin circulation, our aim was to determine whether inducible NO synthase (iNOS) upregulation attenuates NO-dependent cutaneous vasodilation in hypertensive humans. We hypothesized that, with hypertension, localized iNOS inhibition would restore vasodilation in response to NO-dependent stimuli, and iNOS expression would be increased and phosphorylated vasodilator-stimulated phosphoprotein would be decreased. For, in vivo protocols, 4 intradermal microdialysis fibers were placed in 9 hypertensive and 10 normotensive men and women (systolic blood pressure: 146±4 versus 113±2 mm Hg; P<0.001). Microdialysis fibers served as control, iNOS inhibited (1400 W), neuronal NO synthase inhibited (N(ω)-propyl-l-arginine), and nonselective NOS inhibited (N(G)-nitro-l-arginine methyl ester). Cutaneous vascular conductance was calculated (percentage of sodium nitroprusside) during standardized local heating (42°C) and acetylcholine dose-response protocols (0.01, 0.10, 1.00, 5.00, 10.00, 50.00, 100.00 mmol/L). The NO-dependent local heating response was attenuated at control (95±2% versus 76±2% cutaneous vascular conductance; P<0.05) and neuronal NO synthase-inhibited sites (94±4% versus 77±3% cutaneous vascular conductance; P<0.01) in hypertensives. iNOS inhibition augmented the NO-dependent local heating response (93±2% versus 89±10% cutaneous vascular conductance). Acetylcholine-induced vasodilation was attenuated in control sites at doses ≥0.1 mmol/L of acetylcholine in hypertensives and was restored with iNOS inhibition (0.1 mmol/L, P<0.05; 1, 5, and 10 mmol/L, P<0.001; 50 and 100 mmol/L, P<0.01). In vitro iNOS expression was increased (P=0.006) and phosphorylated vasodilator-stimulated phosphoprotein was decreased in skin from hypertensive humans (P=0.04). These data suggest that iNOS is upregulated in essential hypertensive humans and contributes to reduced NO-dependent cutaneous vasodilation.
原发性高血压是一种促炎、促缩血管疾病,与内皮功能障碍和血管内重塑同时存在。我们利用皮肤循环,旨在确定诱导型一氧化氮合酶(iNOS)的上调是否会减轻高血压患者对 NO 依赖的皮肤血管舒张作用。我们假设,在高血压时,局部抑制 iNOS 会恢复对 NO 依赖刺激的血管舒张,并且 iNOS 表达会增加,磷酸化的血管舒张刺激磷酸蛋白会减少。在体内实验中,我们将 4 个真皮内微透析纤维放置在 9 名高血压和 10 名正常血压的男性和女性中(收缩压:146±4 对 113±2mmHg;P<0.001)。微透析纤维用作对照,iNOS 被抑制(1400W),神经元型一氧化氮合酶被抑制(N(ω)-丙基-L-精氨酸),非选择性 NOS 被抑制(N(G)-硝基-L-精氨酸甲酯)。在标准化局部加热(42°C)和乙酰胆碱剂量反应方案(0.01、0.10、1.00、5.00、10.00、50.00、100.00mmol/L)期间,计算皮肤血管导数值(硝普钠的百分比)。在高血压患者中,控制(95±2%对 76±2%皮肤血管导数值;P<0.05)和神经元型一氧化氮合酶抑制部位(94±4%对 77±3%皮肤血管导数值;P<0.01)时,NO 依赖的局部加热反应减弱。iNOS 抑制增强了 NO 依赖的局部加热反应(93±2%对 89±10%皮肤血管导数值)。在高血压患者中,乙酰胆碱诱导的血管舒张在控制部位在乙酰胆碱≥0.1mmol/L 时减弱,并通过 iNOS 抑制恢复(0.1mmol/L,P<0.05;1、5 和 10mmol/L,P<0.001;50 和 100mmol/L,P<0.01)。在体外,高血压患者皮肤中的 iNOS 表达增加(P=0.006),磷酸化的血管舒张刺激磷酸蛋白减少(P=0.04)。这些数据表明,iNOS 在原发性高血压患者中上调,并导致 NO 依赖的皮肤血管舒张减少。